A5026596594- Eating Disorders and Behaviors
- Obesity and Health Practices
- Pharmacology and Obesity Treatment
- Diet and metabolism studies
- Obesity, Physical Activity, Diet
- Bariatric Surgery and Outcomes
- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Regulation of Appetite and Obesity
- Nutritional Studies and Diet
- Health and Lifestyle Studies
- Body Contouring and Surgery
- Obstructive Sleep Apnea Research
- Nutrition and Health in Aging
- Body Image and Dysmorphia Studies
- Obsessive-Compulsive Spectrum Disorders
- Nutrition, Genetics, and Disease
- Cardiac Health and Mental Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Chronic Disease Management Strategies
- Muscle metabolism and nutrition
- Diabetes Management and Education
- Physical Activity and Health
- Sexual function and dysfunction studies
- Neuroscience of respiration and sleep
University of Pennsylvania
2016-2025
California University of Pennsylvania
1983-2024
University of Alabama at Birmingham
2009-2022
Johns Hopkins University
2012-2022
National Institute on Aging
2022
Washington Center for Weight Management and Research
1994-2022
Pennington Biomedical Research Center
2022
Louisiana State University System
2022
Dallas Diabetes Research Center
2022
Medical University of South Carolina
2022
Obesity is a global health challenge with few pharmacologic options. Whether adults obesity can achieve weight loss once-weekly semaglutide at dose of 2.4 mg as an adjunct to lifestyle intervention has not been confirmed.
Weight loss is recommended for overweight or obese patients with type 2 diabetes on the basis of short-term studies, but long-term effects cardiovascular disease remain unknown. We examined whether an intensive lifestyle intervention weight would decrease morbidity and mortality among such patients.In 16 study centers in United States, we randomly assigned 5145 to participate that promoted through decreased caloric intake increased physical activity (intervention group) receive support...
Overweight and obese individuals are encouraged to lose 5-10% of their body weight improve cardiovascular disease (CVD) risk, but data supporting this recommendation limited, particularly for with type 2 diabetes.We conducted an observational analysis participants in the Look AHEAD (Action For Health Diabetes) study (n=5,145, 40.5% male, 37% from ethnic/racial minorities) examined association between magnitude loss changes CVD risk factors at 1 year odds meeting predefined criteria...
OBJECTIVE—The effectiveness of intentional weight loss in reducing cardiovascular disease (CVD) events type 2 diabetes is unknown. This report describes 1-year changes CVD risk factors a trial designed to examine the long-term effects an intensive lifestyle intervention on incidence major events. RESEARCH DESIGN AND METHODS—This study consisted multicentered, randomized, controlled 5,145 individuals with diabetes, aged 45–74 years, BMI >25 kg/m2 (>27 if taking insulin). An...
Weight-loss medications are recommended as an adjunct to a comprehensive program of diet, exercise, and behavior therapy but typically prescribed with minimal or no lifestyle modification. This practice is likely limit therapeutic benefits. In this one-year trial, we randomly assigned 224 obese adults receive 15 mg sibutramine per day alone, delivered by primary care provider in eight visits 10 minutes each; lifestyle-modification counseling 30 group sessions; plus sessions (i.e., combined...
Diagnostic criteria have been developed for a new eating disorder, binge disorder (BED), to describe the many individuals who problems with recurrent but do not engage in characteristic compensatory behaviors of bulimia nervosa, vomiting, or use laxatives. The results multisite field trial involving 1,984 subjects indicate that is common (30.1%) among attending hospital-affiliated weight control programs, relatively rare community (2.0%). more females than males and associated severity...
Binge eating disorder (BED) is a new that describes the disturbance of large number individuals who suffer from recurrent binge but do not regularly engage in compensatory behaviors to avoid weight gain seen bulimia nervosa. This multisite study BED involved 1,785 subjects drawn 18 control programs, 942 five nonpatient community samples, and 75 patients with Approximately 29% programs met criteria for BED. In samples was more common than purging The validity supported by its strong...
Abstract Objective : This study was designed to assess physicians’ attitudes toward obese patients and the causes treatment of obesity. Research Methods Procedures A questionnaire assessed in 2 geographically representative national random samples 5000 primary care physicians. In one sample ( N = 2500), obesity defined as a BMI 30 40 kg/m , other > 40. Results Six hundred twenty physicians responded. They rated physical inactivity significantly more important than any cause p <...
The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on weight loss maintenance in people overweight or obesity is unknown.To compare continued once-weekly subcutaneous 2.4 mg, switch to placebo for (both lifestyle intervention) adults after 20-week run-in semaglutide titrated mg weekly.Randomized, double-blind, 68-week phase 3a withdrawal study conducted at 73 sites 10 countries from June 2018 March 2020 body mass index least 30 (or...
<h3>Importance</h3> Weight loss improves cardiometabolic risk factors in people with overweight or obesity. Intensive lifestyle intervention and pharmacotherapy are the most effective noninvasive weight approaches. <h3>Objective</h3> To compare effects of once-weekly subcutaneous semaglutide, 2.4 mg vs placebo for management as an adjunct to intensive behavioral therapy initial low-calorie diet adults <h3>Design, Setting, Participants</h3> Randomized, double-blind, parallel-group, 68-week,...
InvestigatorsIMPORTANCE Phase 3 trials have not compared semaglutide and liraglutide, glucagon-like peptide-1 analogues available for weight management.OBJECTIVE To compare the efficacy adverse event profiles of once-weekly subcutaneous semaglutide, 2.4 mg, vs once-daily 3.0 mg (both with diet physical activity), in people overweight or obesity.DESIGN, SETTING, AND PARTICIPANTS Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment:...
OBJECTIVE To assess the risk factors for presence and severity of obstructive sleep apnea (OSA) among obese patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Unattended polysomnography was performed in 306 participants. RESULTS Over 86% participants had OSA an apnea-hypopnea index (AHI) ≥5 events/h. The mean AHI 20.5 ± 16.8 A total 30.5% moderate (15 ≤ &lt;30), 22.6% severe (AHI ≥30). Waist circumference (odds ratio 1.1; 95% CI 1.0–1.1; P = 0.03) significantly related to OSA....
In view of the recent demonstration that obesity in animals and humans is associated with an increase tumor necrosis factor-alpha (TNFalpha) expression, this expression falls weight loss, TNFalpha may specifically inhibit insulin action, possibility be a mediator resistance has been raised. We have undertaken study to investigate whether serum concentrations are elevated obese subjects, they fall after parallels release glucose challenge. Obese patients (age range: 25-54, mean +/- SD: 96.4...